Department of Health and Human Services March 14, 2006 – Federal Register Recent Federal Regulation Documents

Guidance for Industry on Prescription Drug Marketing Act-Donation of Prescription Drug Samples to Free Clinics; Availability
Document Number: E6-3532
Type: Notice
Date: 2006-03-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled ``Prescription Drug Marketing ActDonation of Prescription Drug Samples to Free Clinics.'' The guidance provides information for free clinics that receive donated prescription drug samples from licensed practitioners or other charitable institutions. The guidance discusses concerns that have been expressed by certain individuals regarding regulatory requirements for drug sample donations. The guidance announces that FDA, after reviewing an independent study report analyzing the potential effects of the regulations on free clinics, has decided to propose revisions to those regulations. In the interim, FDA intends to exercise its enforcement discretion and does not intend to object if a free clinic fails to comply with certain regulatory requirements for drug sample donations.
Center for Scientific Review; Notice of Closed Meetings
Document Number: 06-2400
Type: Notice
Date: 2006-03-14
Agency: Department of Health and Human Services, National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Document Number: 06-2399
Type: Notice
Date: 2006-03-14
Agency: Department of Health and Human Services, National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings
Document Number: 06-2398
Type: Notice
Date: 2006-03-14
Agency: Department of Health and Human Services, National Institutes of Health
Oral Dosage Form New Animal Drugs; Sulfamerazine, Sulfamethazine, and Sulfaquinoxaline Powder
Document Number: 06-2396
Type: Rule
Date: 2006-03-14
Agency: Food and Drug Administration, Department of Health and Human Services
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a new animal drug application (NADA) filed by Alpharma Inc. The NADA provides revised labeling for a soluble powder containing sulfamerazine, sulfamethazine, and sulfaquinoxaline used in drinking water of chickens and turkeys as an aid in the control of coccidiosis and acute fowl cholera.
Changes to the National Registry of Evidence-Based Programs and Practices (NREPP)
Document Number: 06-2313
Type: Notice
Date: 2006-03-14
Agency: Department of Health and Human Services, Substance Abuse and Mental Health Service Administration, Substance Abuse and Mental Health Services Administration
The Substance Abuse and Mental Health Services Administration (SAMHSA) is committed to preventing the onset and reducing the progression of mental illness, substance abuse, and substance-related problems among all individuals, including youth. As part of this effort, SAMHSA has expanded and refined the agency's National Registry of Evidence-based Programs and Practices (NREPP) based on a systematic analysis and consideration of public comments received in response to a previous Federal Register notice (70 FR 50381, Aug. 26, 2005). This Federal Register notice summarizes SAMHSA's redesign of NREPP as a decision support tool for promoting a greater adoption of evidence-based interventions within typical community-based settings, and provides an opportunity for interested parties to become familiar with the new system.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.